Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis-Reference-Cited by-同舟云学术

Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis

Published:2014-03-04 Issue:7 Volume:53 Page:1245-1249
ISSN:1462-0332
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Geikowski Tilman,Becker Ingrid,Horneff Gerd

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/53/7/1245/10652424/ket490.pdf

Reference15 articles.

1. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis;Lovell;Arthritis Rheum,2008

2. Report on malignancies in the German juvenile idiopathic arthritis registry;Horneff;Rheumatology,2011

3. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis;Bartoli;Ann Rheum Dis,2008

4. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis;Woo;Arthritis Rheum,2000

5. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001;Petty;J Rheumatol,2004

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials;Arthritis Care & Research;2023-01-18

2. The Role of Serum Calprotectin in Defining Disease Outcomes in Non-Systemic Juvenile Idiopathic Arthritis: A Pilot Study;International Journal of Molecular Sciences;2023-01-14

3. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis;Rheumatology;2022-09-15

4. Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial;Arthritis & Rheumatology;2021-02-09

5. Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis;Frontiers in Pharmacology;2021-02-02